Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1454 ARTÍCULOS , VIENDO DEL 256 AL 270

Neuroprotective effects of leptin in the context of obesity and metabolic disorders

Davis C, Mudd J, Hawkins M.

Neurobiol Dis. 2014 Dec;72 Pt A(Pt A):61-71. doi: 10.1016/j.nbd.2014.04.012. Epub 2014 Apr 26.

Immunomodulation and AD--down but not out

Knight EM, Gandy S.

J Clin Immunol. 2014 Jul;34 Suppl 1:S70-3. doi: 10.1007/s10875-014-0039-y. Epub 2014 Apr 30.

Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies

O'Malley TT, Oktaviani NA, Zhang D, Lomakin A, O'Nuallain B, Linse S, Benedek GB, Rowan MJ, Mulder FA, Walsh DM.

Biochem J. 2014 Aug 1;461(3):413-26. doi: 10.1042/BJ20140219.

Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease

Prvulovic D, Schneider B.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):1039-50. doi: 10.1517/17425255.2014.915028. Epub 2014 Apr 30.

Confirmatory factor analysis of the quality of life in Alzheimer's disease scale in patients with Alzheimer's disease

Gómez-Gallego M, Gomez-García J, Ato-García M.

Exp Aging Res. 2014;40(3):266-79. doi: 10.1080/0361073X.2014.896664.

ACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer's disease

Koronyo-Hamaoui M, Shah K, Koronyo Y, Bernstein E, Giani JF, Janjulia T, Black KL, Shi PD, Gonzalez-Villalobos RA, Fuchs S, Shen XZ, Bernstein KE.

Curr Hypertens Rep. 2014 Jul;16(7):444. doi: 10.1007/s11906-014-0444-x.

Antemortem MRI findings associated with microinfarcts at autopsy

Raman MR, Preboske GM, Przybelski SA, Gunter JL, Senjem ML, Vemuri P, Murphy MC, Murray ME, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Dickson DW, Jack CR Jr, Kantarci K.

Neurology. 2014 Jun 3;82(22):1951-8. doi: 10.1212/WNL.0000000000000471. Epub 2014 May 2.

[Periodontal disease]

Michikawa M.

Nihon Rinsho. 2014 Apr;72(4):744-8.

Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations

Xu J, Kong X, Qiu L, Geng X, Hu Y, Wang Y.

Expert Opin Ther Pat. 2014 Jul;24(7):791-800. doi: 10.1517/13543776.2014.915943. Epub 2014 May 5.

Rethinking dementia

Dennison R.

Br J Community Nurs. 2014 Jan;19(1):5. doi: 10.12968/bjcn.2014.19.1.5.

Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status

Ramirez MJ, Lai MK, Tordera RM, Francis PT.

Drugs. 2014 May;74(7):729-36. doi: 10.1007/s40265-014-0217-5.

Transient dynamics of Aβ contribute to toxicity in Alzheimer's disease

Hubin E, van Nuland NA, Broersen K, Pauwels K.

Cell Mol Life Sci. 2014 Sep;71(18):3507-21. doi: 10.1007/s00018-014-1634-z. Epub 2014 May 7.

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease

Bayer TA, Wirths O.

Acta Neuropathol. 2014;127(6):787-801. doi: 10.1007/s00401-014-1287-x. Epub 2014 May 7.

[Acetylcholinesterase inhibitors for treatment of Alzheimer's disease]

Shinagawa S, Shigeta M.

Brain Nerve. 2014 May;66(5):507-16.

Letter to the Editor/Case report: why should we not tube-feed patients with severe Alzheimer dementia?

van Bruchem-Visser RL, Oudshoorn C, Mattace Raso FU.

Best Pract Res Clin Gastroenterol. 2014 Apr;28(2):255-6. doi: 10.1016/j.bpg.2014.02.009. Epub 2014 Mar 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias